Figure 3
Figure 3. aPC induces dimerization of PAR-2 and PAR-3, which is required for apoptosis inhibition in human podocytes. (A) Representative immunoblots of immunoprecipitates showing heterodimerization of PAR-2 and PAR-3 after treatment with aPC (20nM) at different time points as indicated (top panel) and bar graphs summarizing the results (bottom panel). (B) Representative immunoblots of immunoprecipitates showing heterodimerization of PAR-2 and PAR-3 after treatment with aPC (20nM) for 15 minutes in the presence or absence of PAR-3 blocking antibody. PAR-2 IP indicates PAR-2 immunoprecipitation; PAR-3 IP, PAR-3 immunoprecipitation; anti–PAR-3, blocking antibody, 20 μg/mL; and AU, arbitrary units. Data are mean ± SEM of at least 3 independent experiments. *P < .05 vs control (ANOVA).

aPC induces dimerization of PAR-2 and PAR-3, which is required for apoptosis inhibition in human podocytes. (A) Representative immunoblots of immunoprecipitates showing heterodimerization of PAR-2 and PAR-3 after treatment with aPC (20nM) at different time points as indicated (top panel) and bar graphs summarizing the results (bottom panel). (B) Representative immunoblots of immunoprecipitates showing heterodimerization of PAR-2 and PAR-3 after treatment with aPC (20nM) for 15 minutes in the presence or absence of PAR-3 blocking antibody. PAR-2 IP indicates PAR-2 immunoprecipitation; PAR-3 IP, PAR-3 immunoprecipitation; anti–PAR-3, blocking antibody, 20 μg/mL; and AU, arbitrary units. Data are mean ± SEM of at least 3 independent experiments. *P < .05 vs control (ANOVA).

Close Modal

or Create an Account

Close Modal
Close Modal